Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration ...Middle East

PR Newswire - News
UPPSALA, Sweden and SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, today announced that they have mutually agreed to terminate their collaboration...

Read More Details
Finally We wish PressBee provided you with enough information of ( Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration )

Apple Storegoogle play

Also on site :